Fingerprint
Dive into the research topics of 'Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: Results of PrE0102'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically